Research article · 15 Apr 2026
Conference abstractPublished 20 Aug 2012
Blood pressure in renal disease: Objectives, surrogate markers and treatment
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
D espite decades of trials, we still are uncertain as to what level we should lower BP to achieve maximal cardiovascular protection in hypertensive patients. Even more nowadays the target for reducing blood pressure in renal disease is under discussion; there is scanty evidence from randomized clinical trials to support a straight blood pressure control control but for proteinuric patients. On the other hand the value of microalbuminuria as surrogate marker of renal disease progression is controversial in hypertensive non diabetic patients. Furthermore, frequently the effects of treatment on glomerular filtration rate ? the more used and useful test for chronic kidney disease- are opposite in several clinical trials. The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing progression of chronic kidney disease as well as cardiovascular morbidity and mortality in renal patients. The renal results of the ACCOMPLISH trial strongly support the recommendation of using calcium channel blockers as second antihypertensive agent added to renin-angiotensin axis blocking drugs. The validity of this data and its relationship with the cumulated evidence on the effects of calcium antagonists (especially new calcium channel blockers which reduce proteinuria) on renal disease progression will be discussed
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Nicolas Roberto Robles”
